Immunome (IMNM) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.76

Estimate

-$0.60

Surprise

-26.8%

Score today

5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Immunome (IMNM) reported a wider loss than forecast — adjusted EPS of -$0.76 against the -$0.60 estimate (a 26.8% shortfall).

• Immunome Analysts Cut Their Forecasts After Q3 Results — benzinga, 2026-11-10
• Stifel Maintains Hold on Immunome, Lowers Price Target to $23 — benzinga, 2026-11-10
• Piper Sandler Maintains Overweight on Immunome, Lowers Price Target to $30 — benzinga, 2026-11-10

TrendMatrix currently rates IMNM Sell at 5.2/10; no pre/post engine snapshot brackets this report.

0 of the last 4 quarters beat the estimate; this quarter's -26.8% surprise compares with a -26.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$18.45

Price target

$31.62

Stop

$17.16

Upside to target

+71.4%

Reward-to-risk

4.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.28B

P/E (fwd)

-7.8

52-week range

$15.46–$30.06

Off 52-week high

38.6%

RSI (14)

53

Volume vs avg

0.22×

Score today

5.2/10